Spots Global Cancer Trial Database for Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Official Title: International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer

Study ID: NCT00840749

Conditions

Non-small Cell Lung Cancer

Interventions

CyberKnife Stereotactic Radiotherapy

Surgery

Study Description

Brief Summary: Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC.

Detailed Description: Objectives: Primary Goal: To compare overall survival at 3 years. Secondary goals: 1. To compare disease specific survival at 3 years. 2. To compare 3 year progression free survival at the treated primary tumor site 3. To compare grade 3 and above acute and/or chronic toxicities. 4. To evaluate predictive value of pre and post treatment PET scan in clinical outcome.